GLP-1 Addiction Treatment on the NHS: England & Wales

A person taking Wegovy for obesity may notice that wine has lost its appeal. Someone using semaglutide for type 2 diabetes may find themselves smoking fewer cigarettes without planning to. The natural next question is often practical rather than scientific: is GLP-1 addiction treatment on the NHS available in England or Wales?

The clear answer: no GLP-1 medicine is currently an approved or routinely commissioned NHS treatment for alcohol dependence or smoking cessation in England or Wales. Semaglutide is being researched for addiction, and early results are promising, but Wegovy and Ozempic should not currently be prescribed or purchased on the assumption that they are established anti-addiction medicines.

This does not mean the research is unimportant. It means the evidence and NHS treatment pathway have not yet reached the point suggested by some headlines. There is a difference between noticing an unexpected benefit, testing that benefit in a clinical trial and making a treatment routinely available from Cardiff to Canterbury.

Why are people asking about GLP-1 medicines and addiction?

GLP-1 receptor agonists were developed around metabolic health. They help regulate blood glucose, slow digestion and affect appetite signals. Semaglutide is found in several branded products, including Ozempic, Wegovy and Rybelsus, but the brands are not interchangeable and do not share exactly the same licensed purposes.

As prescriptions increased, some patients began reporting changes that were not limited to food. A usual drink was left unfinished. The urge to buy cigarettes felt weaker. Thoughts about alcohol seemed less frequent. These accounts were interesting because laboratory studies had already suggested that GLP-1 signalling could influence reward pathways in the brain.

The brain systems involved in appetite overlap with those involved in motivation, learned cues and reinforcement. Researchers are investigating whether GLP-1 medicines reduce the rewarding effect of alcohol or nicotine, dampen cue-triggered craving or produce a wider sense of satiety. Nausea, changes in taste and feeling full may also contribute.

None of this means that addiction is simply another appetite. Alcohol dependence and nicotine dependence involve biology, behaviour, environment and often mental or physical ill health. A medicine that reduces craving could be valuable without being a complete answer.

What has the research found so far?

Semaglutide and alcohol use disorder

In a small randomised trial published in 2025, 48 adults with alcohol use disorder received low-dose weekly semaglutide or placebo for nine weeks. Semaglutide reduced alcohol consumption during a controlled laboratory drinking task. It also reduced weekly craving, drinks per drinking day and heavy-drinking days compared with placebo.

However, it did not significantly improve every outcome. Average drinks per calendar day and the number of drinking days did not significantly change. Participants were not seeking alcohol treatment, most were overweight or living with obesity, and follow-up was short. The study is good reason for larger trials, not enough evidence for routine prescribing.

A large Swedish observational study found that people with diagnosed alcohol use disorder had fewer alcohol-related hospital admissions during periods when they used GLP-1 medicines, particularly semaglutide. Observational evidence can reveal an important signal but cannot prove that the medicine itself caused the improvement.

Semaglutide and cigarette smoking

The nicotine evidence is earlier. A small 2026 randomised trial studied 24 adults who smoked daily but were not trying to quit. Semaglutide reduced cigarette craving and body weight, yet it did not significantly reduce the number of cigarettes smoked per day. Its main planned laboratory outcomes were also not significant.

An earlier pilot trial found that exenatide, another GLP-1 receptor agonist, used alongside nicotine patches and counselling improved short-term abstinence and reduced post-cessation weight gain. Because established stop-smoking care was provided at the same time, the study did not show that a GLP-1 medicine alone reliably helps people quit.

Question	Position in England and Wales in 2026
Is Wegovy licensed for alcohol addiction?	No. Its authorised and recommended uses do not include alcohol dependence.
Is Ozempic an NHS stop-smoking treatment?	No. It is not an approved treatment for nicotine dependence or smoking cessation.
Can semaglutide reduce alcohol craving?	Possibly for some people. Early trial evidence is encouraging but insufficient for routine treatment.
Can a GP prescribe it off-label?	Off-label prescribing can occur in medicine, but it is a clinician’s individual responsibility. GLP-1 prescribing solely for addiction is not routine NHS care.
Are UK trials taking place?	Yes. British researchers are now studying semaglutide in alcohol dependence, obesity and alcohol-related liver disease.
Is proven help available now?	Yes. Alcohol services, NHS stop-smoking support and established medicines are already available.

Can you get Wegovy for alcohol cravings on the NHS?

Not specifically for alcohol cravings. Wegovy may be prescribed to eligible patients for an authorised indication such as weight management, subject to national guidance, local commissioning and clinical assessment. A person does not become eligible for NHS Wegovy simply because they drink heavily or have alcohol cravings.

If somebody who is appropriately prescribed Wegovy for obesity notices a change in drinking, they should tell their prescriber. That experience may be clinically relevant, particularly if alcohol intake falls quickly or the person has signs of physical dependence. It does not change why the medicine was prescribed.

Ozempic should not be confused with Wegovy. Both contain semaglutide, but Ozempic is associated with type 2 diabetes treatment and is not a general weight-loss or addiction product. Brand recognition is not a medical indication.

How access works in England

England summary: semaglutide can be available through NHS pathways for approved indications, including eligible weight-management patients, but it is not commissioned as alcohol- or nicotine-addiction treatment. Alcohol and stop-smoking care are usually accessed through local services, a GP, a pharmacy or a council-commissioned provider.

NHS England states that semaglutide for obesity is prescribed through specialist weight-management services for suitable patients. Eligibility, local capacity and the route into a service can vary. Someone in Manchester may encounter a different referral arrangement from someone in rural Norfolk, even though national NICE guidance informs care.

For alcohol problems, a GP can assess physical health and withdrawal risk and direct a patient to the local community alcohol service. Many areas permit self-referral. Treatment may involve motivational work, psychological therapy, medically assisted withdrawal and relapse-prevention medicine.

For smoking, local stop-smoking services offer behavioural support and evidence-based treatments. Depending on suitability and availability, these may include nicotine replacement, varenicline, cytisine or bupropion. Services may run through pharmacies, GP surgeries, high-street clinics, mobile teams, telephone appointments or video calls.

The NHS Smokefree National Helpline for England is 0300 123 1044. A local service can also be found through the NHS website. Treatment combined with specialist support offers a much stronger evidence base than attempting to obtain Ozempic privately for smoking cravings.

How access works in Wales

Wales summary: GLP-1 medicines are not routinely provided for addiction treatment. Wales has national routes for practical help: DAN 24/7 for alcohol and drug concerns, and Help Me Quit for free NHS smoking-cessation support.

A person in Cardiff, Newport, Swansea, Wrexham or a rural Powys community should not assume that they need a hospital specialist before discussing drinking. A GP can assess risk and local substance-misuse services can provide community-based support. The all-Wales DAN 24/7 helpline can give confidential information and help people find an appropriate local service.

DAN 24/7: call 0808 808 2234, at any time of day or night. The service is available for people concerned about their own alcohol or drug use and for relatives or carers seeking guidance.

For smoking, Help Me Quit is the national NHS stop-smoking service for Wales. It offers evidence-based support rather than relying on a person to struggle alone. Call 0800 085 2219, text HMQ to 80818, or request help through the Help Me Quit website.

Services can help someone choose suitable stop-smoking medication and plan around routines, stress and previous relapses. That remains the appropriate Welsh pathway while GLP-1 treatment for nicotine addiction is experimental.

England and Wales: what is the same and what differs?

NICE technology appraisals apply to the NHS in England and Wales, but implementation, service organisation and referral routes are not identical. England uses local integrated care and council-commissioned arrangements; Wales organises healthcare through NHS Wales and health boards, with national services such as Help Me Quit and DAN 24/7.

The central clinical message is the same on both sides of the border:

GLP-1 medicines have approved metabolic and, in some circumstances, cardiovascular uses;
alcohol dependence or nicotine addiction alone is not currently an approved GLP-1 indication;
early addiction research should not be presented as established NHS treatment;
people already prescribed a GLP-1 medicine should report major changes in substance use; and
evidence-based addiction and stop-smoking help is available now.

Why new UK research matters

In August 2026, a four-year, £2.7 million British research project was announced to investigate semaglutide in people living with alcohol dependence, obesity and alcohol-related liver disease. The study is being co-led by researchers connected with the University of Plymouth, University Hospitals Plymouth, Nottingham University Hospitals and the NIHR Biomedical Research Centre in Nottingham.

This is particularly relevant to the NHS. Alcohol-related liver disease, obesity and metabolic illness can occur together, yet services have traditionally had to treat them through different pathways. If semaglutide safely reduces harmful drinking while improving weight and metabolic health, one treatment might affect several risks.

That remains a research question. A study announcement is not a positive result, and a positive result would still require regulatory assessment, NICE evaluation, commissioning decisions and clinical guidance before routine NHS use.

What would need to happen next? Larger trials must show meaningful benefits such as sustained reduction, abstinence, fewer hospital admissions or improved liver outcomes. Researchers must also establish safety, appropriate dosing, duration, relapse after stopping and which patients are most likely to benefit.

Why off-label does not mean automatically available

A UK clinician may sometimes prescribe a licensed medicine for a purpose outside its marketing authorisation. This is called off-label prescribing. It is common in some areas of medicine, but it is not a shortcut around limited evidence or NHS commissioning.

The prescriber must be satisfied that the use is clinically justified, understand the evidence and risks, explain the position to the patient and accept professional responsibility. A GP is not obliged to prescribe semaglutide for addiction because a patient has read an encouraging study.

Private prescribing does not change the evidence either. Paying for Wegovy does not make it a validated alcohol treatment. Reputable prescribers should assess whether a patient meets an authorised indication and whether the medicine is safe.

Do not suddenly stop drinking if you are dependent

Important: sudden alcohol withdrawal can be dangerous. If you experience shaking, sweating, retching, anxiety relieved by alcohol, hallucinations or have previously had a withdrawal seizure, seek medical advice before stopping or rapidly cutting down. Call 999 or go to A&E for a seizure, severe confusion, hallucinations or severe agitation.

This warning is especially relevant when appetite or alcohol interest changes unexpectedly after starting semaglutide. A person may begin drinking much less without realising that their body is dependent. Reduced desire does not guarantee a safe withdrawal.

Contact a GP or local alcohol service. In Wales, DAN 24/7 can help identify local support. In England, use the NHS alcohol-support information or contact the local council-commissioned alcohol service.

What treatment for alcohol dependence is available now?

An assessment should consider drinking pattern, withdrawal history, physical health, mental health, medication, home circumstances and the person’s goals. Treatment does not always begin with the instruction to stop immediately. For somebody at risk of withdrawal, stopping must be planned safely.

Care can include:

a medically assisted community or inpatient withdrawal where appropriate;
individual psychological treatment or structured group support;
acamprosate or oral naltrexone after successful withdrawal for suitable patients;
disulfiram in selected circumstances;
support for liver disease, nutrition, housing or mental health; and
longer-term relapse-prevention planning.

NICE recommends combining relevant relapse-prevention medicines with psychological intervention rather than viewing a tablet as the entire treatment. If GLP-1 medicines eventually enter this field, they are also likely to sit within broader care.

What smoking-cessation treatment is available now?

Someone does not need to wait for a semaglutide smoking trial. Nicotine replacement can be used as a slow-acting patch plus a rapid product such as gum, lozenge, inhalator or mouth spray. Prescription options may include varenicline, cytisine or bupropion, depending on suitability and local arrangements.

Behavioural support helps turn medication into a workable quit plan. An adviser can identify when cigarettes are most difficult to avoid, prepare for withdrawal and adjust treatment. In Birmingham that session might happen in a pharmacy; in North Wales it may be arranged through Help Me Quit by telephone. The setting matters less than using a supported, evidence-based approach.

If you already take semaglutide and your cravings have changed

Do not increase or reduce the dose yourself. Follow the schedule given by your prescriber.
Record what changed. Note alcohol units, cigarettes, cravings, nausea and the timing in relation to injections.
Tell your prescriber. A major change may be clinically relevant, particularly with diabetes, liver disease or alcohol dependence.
Use specialist support. A quieter craving can be an opportunity to make a supported change rather than proof that the underlying problem has disappeared.
Seek urgent help when necessary. Severe abdominal pain, persistent vomiting, dehydration or severe alcohol withdrawal needs prompt assessment.

Frequently asked questions

Can my GP prescribe Ozempic for alcohol addiction?

Ozempic is not licensed or routinely commissioned for alcohol addiction. Although off-label prescribing is legally possible in appropriate circumstances, a GP is not expected to provide it on request when evidence and NHS pathways remain unsettled.

Can I get Wegovy for alcohol cravings in Wales?

Alcohol cravings alone do not make someone eligible for Wegovy. It may be prescribed for an authorised indication if NHS Wales criteria and clinical requirements are met. Contact DAN 24/7 or a GP for help specifically with alcohol.

Can I get semaglutide to stop smoking in England?

Semaglutide is not an approved NHS smoking-cessation treatment. Use a local NHS stop-smoking service, which can offer proven medication and behavioural support.

Does NICE recommend GLP-1 medicines for addiction?

No current NICE recommendation supports a GLP-1 medicine as routine treatment for alcohol dependence or nicotine addiction. NICE guidance does cover semaglutide for particular approved indications and separately covers alcohol and tobacco dependence.

Is Wegovy the same as Ozempic?

They contain the same active ingredient, semaglutide, but are branded, dosed and authorised for different purposes. They should not be treated as interchangeable.

Will the NHS prescribe GLP-1 medicines for addiction in the future?

Possibly, but only if larger trials show sufficient effectiveness and safety, followed by regulatory, NICE and commissioning decisions. It is too early to predict whether or when this will happen.

Where can I get immediate alcohol help in Wales?

Call DAN 24/7 on 0808 808 2234. The confidential helpline is open at all times and can direct people, relatives and carers to appropriate support.

Where can I get help to stop smoking in Wales?

Call Help Me Quit on 0800 085 2219, text HMQ to 80818 or use the Help Me Quit Wales website.

The bottom line for England and Wales

GLP-1 medicines may eventually change how clinicians treat addiction. Early semaglutide research suggests that alcohol craving and some drinking outcomes can fall, while the nicotine evidence hints at reduced craving without yet proving reliable smoking cessation.

For now, Wegovy and Ozempic are not NHS addiction treatments in England or Wales. They should not be bought, borrowed or dose-adjusted to control drinking or smoking. Anyone already prescribed semaglutide who notices a sudden change should discuss it with their clinician—especially if alcohol dependence is possible.

The encouraging part is not only that new treatments may arrive. Effective help already exists: local alcohol services and NHS stop-smoking services in England, and the national DAN 24/7 and Help Me Quit routes in Wales. Research can move forward without asking patients to wait.

References and official support

This article provides general information and does not replace personal medical advice. Eligibility, prescribing arrangements and local services can change; confirm current options with the relevant NHS service.